LongevityMedium Risk

Foxo4-DRI

Also known as: Foxo4-D-Retro-Inverso, Proxofim, Senolytic peptide

Half-life:: Unknown

Administration Routes

intravenoussubcutaneous injection

PeptideBase provides educational research tools and provider discovery. It does not provide medical advice, diagnosis, treatment, prescribing guidance, or dosing instructions. Consult a qualified healthcare professional before making health decisions.

Mechanism of Action

D-retro-inverso peptide that disrupts Foxo4/p53 interaction in senescent cells; restores p53-mediated apoptosis selectively in senescent cells; clears cellular "zombie cells"

A breakthrough senolytic peptide that selectively eliminates senescent cells by restoring their ability to undergo apoptosis. Produced dramatic rejuvenation effects in preclinical studies.

Primary Research Areas

senescent cell clearance
tissue rejuvenation
healthspan extension
senolytic

Risk Profile

Medium Risk

Moderate risk profile in research contexts. Consult a healthcare professional before use.

Regulatory Status

Research OnlyNot Evaluated by FDA

Senolytic D-retro-inverso Foxo4 peptide (de Keizer lab, Netherlands). Eliminates p21-positive senescent cells. No FDA approval, no IND or NDA. Novel research compound only.

Regulatory status reflects publicly available information and may change. This is not legal or medical advice.

Where to Find Foxo4-DRI

No active associated providers listed yet.